{"id":28389,"date":"2025-07-23T08:52:45","date_gmt":"2025-07-23T08:52:45","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/singapore-based-innovative-biomedical-start-up-achieves-strategic-triumph-to-conquer-chinese-med-tech-market\/"},"modified":"2025-07-23T08:52:45","modified_gmt":"2025-07-23T08:52:45","slug":"singapore-based-innovative-biomedical-start-up-achieves-strategic-triumph-to-conquer-chinese-med-tech-market-2","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=28389","title":{"rendered":"Singapore-Based Innovative Biomedical Start-Up Achieves &#8216;Strategic Triumph&#8217; to Conquer Chinese Med-Tech Market"},"content":{"rendered":"<ul type=\"disc\">\n<li><b> NMPA grants Syntellix product approval for the world&#8217;s most important future market with more than 1.4 billion people<\/b><\/li>\n<li><b> Syntellix&#8217; product approval for <span class=\"xn-location\">China<\/span> is the largest and most important success in the company&#8217;s history; product approval in <span class=\"xn-location\">China<\/span> was the company&#8217;s most important strategic and operational goal<\/b><\/li>\n<li><b> Syntellix had previously already been granted the accelerated &#8216;innovative pathway&#8217; by the NMPA due to the exceptional benefits of its products<\/b><\/li>\n<li><b> In total, product approvals for Syntellix products have accumulated to date in countries with more than 5.5 billion inhabitants; product approvals had already been achieved in 73 countries and regions on five continents before current success in <span class=\"xn-location\">China<\/span><\/b><\/li>\n<li><b> Development of the prioritized core markets of <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">India<\/span>, and ASEAN is being carried out via Syntellix Asia Pte Ltd in <span class=\"xn-location\">Singapore<\/span> as manufacturing facility &amp; sales hub<\/b><\/li>\n<li><b> Syntellix Asia Pte Ltd has been supported by the Singapore Economic Development Board (EDB); Syntellix AG targets IPO on the Singapore Exchange (SGX)<\/b><\/li>\n<li><b> Syntellix and Syntellix Asia CEO Claassen: &#8220;After 7 years of focusing on <span class=\"xn-location\">China<\/span>, we have achieved what almost everyone considered impossible. As a startup with its operational heart in <span class=\"xn-location\">Singapore<\/span>, we have written a pioneering story worldwide, whose global medical success can now no longer be stopped. I sincerely thank the Singapore Economic Development Board (EDB) for its far-sighted contribution to the operational and structural foundation of our rollout in <span class=\"xn-location\">Asia<\/span> by providing expertise and financial support for the establishment and expansion of our production facility in <span class=\"xn-location\">Singapore<\/span>, which will now also become an <span class=\"xn-location\">Asia<\/span>-wide and global sales hub as planned.&#8221;<\/b><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">HANOVER, Germany<\/span>, and <span class=\"xn-location\">BEIJING<\/span> and <span class=\"xn-location\">SINGAPORE<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">July 23, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Syntellix AG, parent company of <span class=\"xn-location\">Singapore<\/span>-based, Syntellix Asia Pte Ltd, has received product approval for <span class=\"xn-location\">the People&#8217;s Republic of China<\/span> from the Chinese NMPA (National Medical Products Administration) in <span class=\"xn-location\">Beijing<\/span>, which is responsible for the government regulation, registration, and monitoring of medical devices for the Chinese market. This product approval for the world&#8217;s most important future market, with more than 1.4 billion people, is by far the greatest and most important success in the company&#8217;s history. Syntellix AG had declared the development of the vast Chinese market its top strategic priority following Professor Dr <span class=\"xn-person\">Utz Claassen&#8217;s<\/span> assumption of office as CEO of the company. After Syntellix had already previously been granted the accelerated &#8216;innovative pathway&#8217; by the NMPA due to the particular advantages of its products, the initial approval process has now been completed extremely successfully. It was the most complex, intensive, and sophisticated approval process Syntellix has ever undergone in terms of product safety and quality management systems.<\/p>\n<p>Syntellix now has obtained product approvals in countries with more than 5.5 billion inhabitants, or more than two thirds of the world&#8217;s population. Syntellix had previously received product approvals in 73 countries and regions on five continents, including all of <span class=\"xn-location\">Europe<\/span>, <span class=\"xn-location\">Australia<\/span> and <span class=\"xn-location\">New Zealand<\/span>, <span class=\"xn-location\">South Africa<\/span>, <span class=\"xn-location\">Singapore<\/span>, <span class=\"xn-location\">Israel<\/span>, and <span class=\"xn-location\">Saudi Arabia<\/span>, as well as fast-growing, demographically dynamic countries such as <span class=\"xn-location\">Indonesia<\/span>, <span class=\"xn-location\">Vietnam<\/span>, <span class=\"xn-location\">the Philippines<\/span>, and <span class=\"xn-location\">Thailand<\/span>, as well as the world&#8217;s most populous country \u2013 <span class=\"xn-location\">India<\/span>. <span class=\"xn-location\">China<\/span> and <span class=\"xn-location\">India<\/span>, with a combined population of almost 3 billion, open up entirely new dimensions of potential for the company in many respects. Syntellix&#8217; highly innovative bioabsorbable metallic implants are produced by Syntellix Asia Pte Ltd which is based in JTC&#8217;s Tuas Biomedical Park. The Economic Development Board (EDB) had provided initial grants to Syntellix to support the establishment of its manufacturing presence and global sales hub in <span class=\"xn-location\">Singapore<\/span>.<\/p>\n<p>With the product approval now achieved in <span class=\"xn-location\">China<\/span>, labelled by German news platform &#8216;Pressefeuer&#8217; a &#8216;strategic triumph&#8217; that could revolutionize the world of biomedical engineering and is a decisive step for the <span class=\"xn-location\">Hanover<\/span>-based company&#8217;, Syntellix has achieved its most important strategic and operational goal. The strategic decision to develop the prioritized core markets of <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">India<\/span>, and ASEAN through Syntellix Asia Pte Ltd in <span class=\"xn-location\">Singapore<\/span>, and to locate and expand the main production site in the ultra-modern and highly efficient island nation of <span class=\"xn-location\">Singapore<\/span>, has proven to be both expedient and entirely correct. Establishing an <span class=\"xn-location\">Asia<\/span>-centric production chain was strategically and operationally the right decision, as the production and sales hub in <span class=\"xn-location\">Singapore<\/span> can supply and serve most of the world better and faster than from <span class=\"xn-location\">Germany<\/span> or <span class=\"xn-location\">Europe<\/span>. More than 3.5 billion people live in <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">India<\/span>, and the ASEAN region alone, which is more than 40 times the population of the Federal Republic of <span class=\"xn-location\">Germany<\/span>, while at the same time experiencing significantly greater dynamics in terms of population growth, market growth, and economic power and perspectives.<\/p>\n<p>For this purpose \u2013 establishing and expanding production in <span class=\"xn-location\">Singapore<\/span>, tapping into the South Asian, Southeast Asian, and East Asian markets, and obtaining the necessary product approvals, particularly in <span class=\"xn-location\">China<\/span>, \u2013 Syntellix, CEO Professor, Dr <span class=\"xn-person\">Utz Claassen<\/span>, who is also Executive Chairman &amp; CEO of Syntellix Asia Pte Ltd in <span class=\"xn-location\">Singapore<\/span>, relocated his residence from <span class=\"xn-location\">Germany<\/span> to <span class=\"xn-location\">Singapore<\/span> more than five years ago in consultation and coordination with the Supervisory Board of Syntellix AG.<\/p>\n<p>Syntellix CEO Professor <span class=\"xn-person\">Utz Claassen<\/span> thus commented very positively on the product approval now achieved in <span class=\"xn-location\">China<\/span>: &#8220;After more than 17 years of work and more than 7 years of focusing on <span class=\"xn-location\">China<\/span> alone, we have achieved what almost everyone considered impossible. As a startup from <span class=\"xn-location\">Hanover<\/span> with ist operational heart in <span class=\"xn-location\">Singapore<\/span>, we have written a pioneering story worldwide, whose global medical success is now unstoppable. Those who win in <span class=\"xn-location\">China<\/span> are strategically and operationally ideally positioned. The largest hospitals in <span class=\"xn-location\">China<\/span> individually have higher patient volumes and more operations for our highly innovative products than most countries in the European Union. Without neglecting our homeland, we are proud and grateful to now be able to use our products, which are so beneficial for patients, users, and the healthcare system, in <span class=\"xn-location\">China<\/span>, with its 5,000 years of cultural history, its magnificent medical tradition, and its unique future prospects. This is a game changer for our company, both qualitatively and quantitatively.&#8221;<\/p>\n<p>Claassen emphasizes both the abstract and concrete positive conditions for the successful development of Syntellix&#8217; activities in <span class=\"xn-location\">Asia<\/span>, and also specifically in <span class=\"xn-location\">Singapore<\/span>, and he is grateful for the very positive environment here: &#8220;I would like to expressly thank our outstanding Chinese partners for their tremendous support and cooperation, and the NMPA for an outstandingly differentiated and structured approval process. I would also like to sincerely thank the Singapore Economic Development Board (EDB) for its far-sighted contribution to the operational and structural foundation of our rollout in <span class=\"xn-location\">Asia<\/span> by providing expertise and financial support for the establishment and expansion of our production facility in <span class=\"xn-location\">Singapore<\/span>, which will now also become an <span class=\"xn-location\">Asia<\/span>-wide and global sales hub as planned. This will create many attractive jobs in <span class=\"xn-location\">Singapore<\/span> and set new international standards in biomedical engineering under market conditions that are not found in <span class=\"xn-location\">Germany<\/span> or <span class=\"xn-location\">Europe<\/span>, and building on government funding from the Republic of <span class=\"xn-location\">Singapore<\/span>.&#8221;<\/p>\n<p>Syntellix AG, as a joint-stock company under German stockholding law already a public company, also targets an IPO on the Singapore Exchange (SGX), the preparations of which have already been ongoing for several years with the help of Singaporean banks and law firms, well supported by SGX management under the leadership of its CEO Mr <span class=\"xn-person\">Loh Boon Chye<\/span> and coordinated by Ms <span class=\"xn-person\">Alice Gwee<\/span>.<\/p>\n<p><b>About Syntellix:<\/b><\/p>\n<p>Syntellix AG, a global pioneer in biomedical engineering, materials, and life sciences, is the only company in the world with approvals for bioabsorbable metallic implants in more than 70 countries on five continents, tens of thousands of successful surgeries, and the highest level of patient satisfaction. Syntellix is a global protagonist and market and technology leader in the field of bioabsorbable metallic orthopaedic implants. The company has received numerous prestigious awards and prizes, including the Innovation Award of the German Economy, the German Healthcare Industry Future Award, the German Medical Award, the STEP Award, the &#8220;Innovator of the Year&#8221; award, the German Innovation Award in Gold, and the Sustainability Award as &#8220;Product of the Year.&#8221; More than 50 medical and scientific publications have meanwhile documented the safety, efficacy, and reliability of the MAGNEZIX\u00ae implants developed by Syntellix, which have been described as &#8220;advantageous&#8221; and even &#8220;clinically superior&#8221; to conventional titanium implants for numerous clinical applications.<\/p>\n<p>Syntellix Asia Pte Ltd in <span class=\"xn-location\">Singapore<\/span> is a wholly-owned subsidiary of Syntellix AG. It is the operational heart of the group. The manufacturing facility for the highly innovative MAGNEZIX\u00ae implants is located in <span class=\"xn-location\">Singapore<\/span>, in JTC&#8217;s Biomedical Park in Tuas. Syntellix Asia Pte Ltd, which in turn has the subsidiaries Syntellix China Pte Ltd, Syntellix Philippines Incorporated in <span class=\"xn-location\">San Juan<\/span> City, and Syntellix India Private Limited in <span class=\"xn-location\">New Delhi<\/span> and Jaipur, Rajasthan, serves not only the internationally leading medical hub of <span class=\"xn-location\">Singapore<\/span> itself with its numerous world-class hospitals, but also major markets in countries throughout the ASEAN region, including <span class=\"xn-location\">Thailand<\/span>, <span class=\"xn-location\">Malaysia<\/span>, <span class=\"xn-location\">Vietnam<\/span>, and <span class=\"xn-location\">Indonesia<\/span>.&#8221;<\/p>\n<p><b>Contact: <\/b><br \/>T +49 511 270 413 50<br \/>F +49 511 270 413 79<br \/><a href=\"mailto:info@syntellix.com\" target=\"_blank\" rel=\"nofollow\">info@syntellix.com<\/a><br \/><a href=\"https:\/\/www.syntellix.com\/\" target=\"_blank\" rel=\"nofollow\">www.syntellix.com<\/a>\u00a0<\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<ul type=\"disc\">\n<li><b> NMPA grants Syntellix product approval for the world&#8217;s most important future market with more than 1.4 billion people<\/b><\/li>\n<li><b> Syntellix&#8217; product approval for <span class=\"xn-location\">China<\/span> is the largest and most important success in the company&#8217;s history; product approval in <span class=\"xn-location\">China<\/span> was the company&#8217;s most important strategic and operational goal<\/b><\/li>\n<li><b> Syntellix had previously already been granted the accelerated &#8216;innovative pathway&#8217; by the NMPA due to the exceptional benefits of its products<\/b><\/li>\n<li><b> In total, product approvals for Syntellix products have accumulated to date in countries with more than 5.5 billion inhabitants; product approvals had already been achieved in 73 countries and regions on five continents before current success in <span class=\"xn-location\">China<\/span><\/b><\/li>\n<li><b> Development of the prioritized core markets of <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">India<\/span>, and ASEAN is being carried out via Syntellix Asia Pte Ltd in <span class=\"xn-location\">Singapore<\/span> as manufacturing facility &amp; sales hub<\/b><\/li>\n<li><b> Syntellix Asia Pte Ltd has been supported by the Singapore Economic Development Board (EDB); Syntellix AG targets IPO on the Singapore Exchange (SGX)<\/b><\/li>\n<li><b> Syntellix and Syntellix Asia CEO Claassen: &#8220;After 7 years of focusing on <span class=\"xn-location\">China<\/span>, we have achieved what almost everyone considered impossible. As a startup with its operational heart in <span class=\"xn-location\">Singapore<\/span>, we have written a pioneering story worldwide, whose global medical success can now no longer be stopped. I sincerely thank the Singapore Economic Development Board (EDB) for its far-sighted contribution to the operational and structural foundation of our rollout in <span class=\"xn-location\">Asia<\/span> by providing expertise and financial support for the establishment and expansion of our production facility in <span class=\"xn-location\">Singapore<\/span>, which will now also become an <span class=\"xn-location\">Asia<\/span>-wide and global sales hub as planned.&#8221;<\/b><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">HANOVER, Germany<\/span>, and <span class=\"xn-location\">BEIJING<\/span> and <span class=\"xn-location\">SINGAPORE<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">July 23, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Syntellix AG, parent company of <span class=\"xn-location\">Singapore<\/span>-based, Syntellix Asia Pte Ltd, has received product approval for <span class=\"xn-location\">the People&#8217;s Republic of China<\/span> from the Chinese NMPA (National Medical Products Administration) in <span class=\"xn-location\">Beijing<\/span>, which is responsible for the government regulation, registration, and monitoring of medical devices for the Chinese market. This product approval for the world&#8217;s most important future market, with more than 1.4 billion people, is by far the greatest and most important success in the company&#8217;s history. Syntellix AG had declared the development of the vast Chinese market its top strategic priority following Professor Dr <span class=\"xn-person\">Utz Claassen&#8217;s<\/span> assumption of office as CEO of the company. After Syntellix had already previously been granted the accelerated &#8216;innovative pathway&#8217; by the NMPA due to the particular advantages of its products, the initial approval process has now been completed extremely successfully. It was the most complex, intensive, and sophisticated approval process Syntellix has ever undergone in terms of product safety and quality management systems.<\/p>\n<p>Syntellix now has obtained product approvals in countries with more than 5.5 billion inhabitants, or more than two thirds of the world&#8217;s population. Syntellix had previously received product approvals in 73 countries and regions on five continents, including all of <span class=\"xn-location\">Europe<\/span>, <span class=\"xn-location\">Australia<\/span> and <span class=\"xn-location\">New Zealand<\/span>, <span class=\"xn-location\">South Africa<\/span>, <span class=\"xn-location\">Singapore<\/span>, <span class=\"xn-location\">Israel<\/span>, and <span class=\"xn-location\">Saudi Arabia<\/span>, as well as fast-growing, demographically dynamic countries such as <span class=\"xn-location\">Indonesia<\/span>, <span class=\"xn-location\">Vietnam<\/span>, <span class=\"xn-location\">the Philippines<\/span>, and <span class=\"xn-location\">Thailand<\/span>, as well as the world&#8217;s most populous country \u2013 <span class=\"xn-location\">India<\/span>. <span class=\"xn-location\">China<\/span> and <span class=\"xn-location\">India<\/span>, with a combined population of almost 3 billion, open up entirely new dimensions of potential for the company in many respects. Syntellix&#8217; highly innovative bioabsorbable metallic implants are produced by Syntellix Asia Pte Ltd which is based in JTC&#8217;s Tuas Biomedical Park. The Economic Development Board (EDB) had provided initial grants to Syntellix to support the establishment of its manufacturing presence and global sales hub in <span class=\"xn-location\">Singapore<\/span>.<\/p>\n<p>With the product approval now achieved in <span class=\"xn-location\">China<\/span>, labelled by German news platform &#8216;Pressefeuer&#8217; a &#8216;strategic triumph&#8217; that could revolutionize the world of biomedical engineering and is a decisive step for the <span class=\"xn-location\">Hanover<\/span>-based company&#8217;, Syntellix has achieved its most important strategic and operational goal. The strategic decision to develop the prioritized core markets of <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">India<\/span>, and ASEAN through Syntellix Asia Pte Ltd in <span class=\"xn-location\">Singapore<\/span>, and to locate and expand the main production site in the ultra-modern and highly efficient island nation of <span class=\"xn-location\">Singapore<\/span>, has proven to be both expedient and entirely correct. Establishing an <span class=\"xn-location\">Asia<\/span>-centric production chain was strategically and operationally the right decision, as the production and sales hub in <span class=\"xn-location\">Singapore<\/span> can supply and serve most of the world better and faster than from <span class=\"xn-location\">Germany<\/span> or <span class=\"xn-location\">Europe<\/span>. More than 3.5 billion people live in <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">India<\/span>, and the ASEAN region alone, which is more than 40 times the population of the Federal Republic of <span class=\"xn-location\">Germany<\/span>, while at the same time experiencing significantly greater dynamics in terms of population growth, market growth, and economic power and perspectives.<\/p>\n<p>For this purpose \u2013 establishing and expanding production in <span class=\"xn-location\">Singapore<\/span>, tapping into the South Asian, Southeast Asian, and East Asian markets, and obtaining the necessary product approvals, particularly in <span class=\"xn-location\">China<\/span>, \u2013 Syntellix, CEO Professor, Dr <span class=\"xn-person\">Utz Claassen<\/span>, who is also Executive Chairman &amp; CEO of Syntellix Asia Pte Ltd in <span class=\"xn-location\">Singapore<\/span>, relocated his residence from <span class=\"xn-location\">Germany<\/span> to <span class=\"xn-location\">Singapore<\/span> more than five years ago in consultation and coordination with the Supervisory Board of Syntellix AG.<\/p>\n<p>Syntellix CEO Professor <span class=\"xn-person\">Utz Claassen<\/span> thus commented very positively on the product approval now achieved in <span class=\"xn-location\">China<\/span>: &#8220;After more than 17 years of work and more than 7 years of focusing on <span class=\"xn-location\">China<\/span> alone, we have achieved what almost everyone considered impossible. As a startup from <span class=\"xn-location\">Hanover<\/span> with ist operational heart in <span class=\"xn-location\">Singapore<\/span>, we have written a pioneering story worldwide, whose global medical success is now unstoppable. Those who win in <span class=\"xn-location\">China<\/span> are strategically and operationally ideally positioned. The largest hospitals in <span class=\"xn-location\">China<\/span> individually have higher patient volumes and more operations for our highly innovative products than most countries in the European Union. Without neglecting our homeland, we are proud and grateful to now be able to use our products, which are so beneficial for patients, users, and the healthcare system, in <span class=\"xn-location\">China<\/span>, with its 5,000 years of cultural history, its magnificent medical tradition, and its unique future prospects. This is a game changer for our company, both qualitatively and quantitatively.&#8221;<\/p>\n<p>Claassen emphasizes both the abstract and concrete positive conditions for the successful development of Syntellix&#8217; activities in <span class=\"xn-location\">Asia<\/span>, and also specifically in <span class=\"xn-location\">Singapore<\/span>, and he is grateful for the very positive environment here: &#8220;I would like to expressly thank our outstanding Chinese partners for their tremendous support and cooperation, and the NMPA for an outstandingly differentiated and structured approval process. I would also like to sincerely thank the Singapore Economic Development Board (EDB) for its far-sighted contribution to the operational and structural foundation of our rollout in <span class=\"xn-location\">Asia<\/span> by providing expertise and financial support for the establishment and expansion of our production facility in <span class=\"xn-location\">Singapore<\/span>, which will now also become an <span class=\"xn-location\">Asia<\/span>-wide and global sales hub as planned. This will create many attractive jobs in <span class=\"xn-location\">Singapore<\/span> and set new international standards in biomedical engineering under market conditions that are not found in <span class=\"xn-location\">Germany<\/span> or <span class=\"xn-location\">Europe<\/span>, and building on government funding from the Republic of <span class=\"xn-location\">Singapore<\/span>.&#8221;<\/p>\n<p>Syntellix AG, as a joint-stock company under German stockholding law already a public company, also targets an IPO on the Singapore Exchange (SGX), the preparations of which have already been ongoing for several years with the help of Singaporean banks and law firms, well supported by SGX management under the leadership of its CEO Mr <span class=\"xn-person\">Loh Boon Chye<\/span> and coordinated by Ms <span class=\"xn-person\">Alice Gwee<\/span>.<\/p>\n<p><b>About Syntellix:<\/b><\/p>\n<p>Syntellix AG, a global pioneer in biomedical engineering, materials, and life sciences, is the only company in the world with approvals for bioabsorbable metallic implants in more than 70 countries on five continents, tens of thousands of successful surgeries, and the highest level of patient satisfaction. Syntellix is a global protagonist and market and technology leader in the field of bioabsorbable metallic orthopaedic implants. The company has received numerous prestigious awards and prizes, including the Innovation Award of the German Economy, the German Healthcare Industry Future Award, the German Medical Award, the STEP Award, the &#8220;Innovator of the Year&#8221; award, the German Innovation Award in Gold, and the Sustainability Award as &#8220;Product of the Year.&#8221; More than 50 medical and scientific publications have meanwhile documented the safety, efficacy, and reliability of the MAGNEZIX\u00ae implants developed by Syntellix, which have been described as &#8220;advantageous&#8221; and even &#8220;clinically superior&#8221; to conventional titanium implants for numerous clinical applications.<\/p>\n<p>Syntellix Asia Pte Ltd in <span class=\"xn-location\">Singapore<\/span> is a wholly-owned subsidiary of Syntellix AG. It is the operational heart of the group. The manufacturing facility for the highly innovative MAGNEZIX\u00ae implants is located in <span class=\"xn-location\">Singapore<\/span>, in JTC&#8217;s Biomedical Park in Tuas. Syntellix Asia Pte Ltd, which in turn has the subsidiaries Syntellix China Pte Ltd, Syntellix Philippines Incorporated in <span class=\"xn-location\">San Juan<\/span> City, and Syntellix India Private Limited in <span class=\"xn-location\">New Delhi<\/span> and Jaipur, Rajasthan, serves not only the internationally leading medical hub of <span class=\"xn-location\">Singapore<\/span> itself with its numerous world-class hospitals, but also major markets in countries throughout the ASEAN region, including <span class=\"xn-location\">Thailand<\/span>, <span class=\"xn-location\">Malaysia<\/span>, <span class=\"xn-location\">Vietnam<\/span>, and <span class=\"xn-location\">Indonesia<\/span>.&#8221;<\/p>\n<p><b>Contact: <\/b><br \/>T +49 511 270 413 50<br \/>F +49 511 270 413 79<br \/><a href=\"mailto:info@syntellix.com\" target=\"_blank\" rel=\"nofollow\">info@syntellix.com<\/a><br \/><a href=\"https:\/\/www.syntellix.com\/\" target=\"_blank\" rel=\"nofollow\">www.syntellix.com<\/a>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-28389","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/28389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28389"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/28389\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}